Skip to content

Randomized, open-label, single dose, cross-over study to evaluate acceptability, ease of intake and preference of two placebo capsule regimens in adolescents aged 12 - <18 years

Randomized, open-label, single dose, cross-over study to evaluate acceptability, ease of intake and preference of two placebo capsule regimens in adolescents aged 12 - <18 years - CLNP023A2011R

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037670
Enrollment
80
Registered
2026-03-10
Start date
2026-03-25
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No specific medical condition is required to participate in the study, as a placebo will be administered to assess the acceptability of the capsules.

Interventions

Group 1: Sequence A: 1 Capsule size 0, single dose administration: Evaluation of swallowability, palatabilty and ease of administration 2 Capsules size 1, single dose administration: Evaluation of

Sponsors

Novartis Pharma AG
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 17 Years

Inclusion criteria

Inclusion criteria: -Age: Adolescents aged 12 - <18 years -Sex: Male or female -Disease and severity: Acutely or chronically ill adolescents -Previous therapy: Not applicable - Other specific requirements: Willingness and capability of participants to read and understand German language and comply with examination procedures -Informed consent: Written informed consent from both parents or legal representatives, and Assent where possible

Exclusion criteria

Exclusion criteria: -Disease/illness: Any impairment of swallowing solids as a consequence of chronic illness (e.g. cerebral palsy), acute illness (e.g. sepsis, respiratory distress, gastroenteritis, respiratory tract infection), or oral deformation, as assessed by the investigator, patients on intensive care unit wards - Intolerance: History of hypersensitivity to any of the ingredients present in the capsules -Pre- and concomitant medication: Any drug that causes nausea, fatigue, or palsy -Intervention: Adolescents in the post-operative period who have yet to commence regular oral feeding -Nutrition: Adolescents who have eaten 1 h before examination and who afterwards feel sick because of the food

Design outcomes

Primary

MeasureTime frame
Acceptability derived as composite endpoint from palatability (as rated by the participant) and swallowability (as rated by the investigator)

Secondary

MeasureTime frame
- Ease of administration of each capsule regimen assessed by a 10-point scoring scale - Preference concerning the two capsule regimens - Swallowing problems

Countries

Germany

Contacts

Public ContactViviane Klingmann

Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie

viviane.klingmann@med.uni-duesseldorf.de+492118107906

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026